Efficacy and safety of ebastine use in patients having chronic spontaneous urticaria


DOI: https://dx.doi.org/10.18565/therapy.2024.4.159-164

Bolieva L.Z., Tseboeva M.B.

1) North Ossetian State Medical Academy of the Ministry of Healthcare of Russia, Vladikavkaz; 2) Diamed LLC, Vladikavkaz
Abstract. Chronic spontaneous urticaria (CSU) is the most common form of chronic urticaria, which represents an actual medical and social problem. The first-line drugs in the treatment of CSU patients are 2nd generation H1-antihistamines.
The aim: to evaluate the efficacy and safety of the 2nd generation of H1-antihistamine drug ebastine in CSU patients.
Material and methods. An open, prospective, monocentric, uncontrolled study of the efficacy and safety of using ebastine in the form of film-coated tablets containing 20 mg of active substance (drug Allergostin, “Scientific and Technological Pharmaceutical Company POLYSAN” LLC, Russia) was performed in patients with CSU. The study included 44 patients (mean age 37.2 ± 14.2 years) with a diagnosis of CSU made in accordance with current clinical guidelines. The study medicine was prescribed 1 tablet orally once a day for 14 days. Efficacy was assessed by the dynamics of the main clinical features of chronic urticaria according to the UAS 7 scale and indicators of urticaria symptoms control in accordance with UCT test, as well as by changes in the subjective condition of patient according to DQLI life quality questionnaire of patients with dermatological diseases. Safety was assessed by recording adverse events (AEs). The duration of the study was 14 days.
Results. The use of ebastine led to a statistically significant reduction in the total score of the number of urticarial rashes and intensity of itching by UAS 7 scale, achieving disease control and improving life quality of patients. AEs identified in 18.2% of patients were mild in severity.
Conclusion. The results of the study proved that ebastine in the form of film-coated tablets containing 20 mg of active substance has clinically significant efficacy and safety in the treatment of CSU in adult patients.
Keywords: safety of H1-antihistamine drugs, efficacy of H1-antihistamine drugs, chronic spontaneous urticaria, ebastine
Read entire article

Literature

1. Баранов А.А., Намазова-Баранова Л.С., Ильина Н.И. с соавт. Современные подходы к ведению пациентов с крапивницей. Педиатрическая фармакология. 2023; 20(5): 454–477. (Baranov A.A., Namazova-Baranova L.S., Il’ina N.I. et al. Modern approaches to the management of patients with urticaria. Pediatricheskaya farmakologiya= Pediatric Pharmacology. 2023; 20(5): 454–477 (In Russ.)).


https://doi.org/10.15690/pf.v20i5.2629. EDN: RLOOTX.


2. Вeck L., Bernstein J., Maurer M. A Review of international recommendations for the diagnosis and management of chronic urticaria. Acta Derm Venereol. 2017; 97(2): 149–58.


https://doi.org/10.2340/00015555-2496. PMID: 27349620.


3. Baiardini I., Giardini A., Pasquali M. et al. Quality of life and patients’ satisfaction in chronic urticaria and respiratory allergy. Allergy. 2003; 58(7): 621–23.


https://doi.org/10.1034/j.1398-9995.2003.00091.x. PMID: 12823121.


4. O’Donnell B.F., Lawlor F., Simpson J. et al. The impact of chronic urticaria on the quality of life. Br J Dermatol. 1997; 136(2): 197–201. PMID: 9068731.


5. Grob J.J., Revuz J., Ortonne J.P. et al. Comparative study of the impact of chronic urticaria, psoriasis and atopic dermatitis on the quality of life. Br J Dermatol. 2005; 152(2): 289–95.


https://doi.org/10.1111/j.1365-2133.2005.06385.x. PMID: 15727641.


6. Poon E., Seed P.T., Greaves M.W., Kobza-Black A. The extent and nature of disability in different urticarial conditions. Br J Dermatol. 1999; 140(4): 667–71.


https://doi.org/10.1046/j.1365-2133.1999.02767.x. PMID: 10233318.


7. Lennox R.D., Leahy M.J. Validation of the Dermatology Life Quality Index as an outcome measure for urticaria-related quality of life. Ann Allergy Asthma Immunol. 2004; 93(2): 142–46.


https://doi.org/10.1016/S1081-1206(10)61466-4. PMID: 15328673.


8. Maurer M., Abuzakouk M., Berard F. et al. The burden of chronic spontaneous urticaria is substantial: Real-world evidence from ASSURE-CSU. Allergy. 2017; 72(12): 2005–16.


https://doi.org/10.1111/all.13209. PMID: 28543019. PMCID: PMC5724512.


9. Клинические рекомендации. Крапивница. Российская ассоциация аллергологов и клинических иммунологов, обще­российская общественная организация «Российское общество дерматовенерологов и косметологов», Союз педиатров России. Рубрикатор клинических рекомендаций Минздрава России. 2023. ID: 264. Доступ: https://cr.minzdrav.gov.ru/schema/264_2 (дата обращения – 27.05.2024). (Clinical guidelines. Urticaria. Russian Association of Allergists and Clinical Immunologists, Russian Society of Dermatovenereologists and Cosmetologists, Union of Pediatricians of Russia. Rubricator of clinical guidelines of the Ministry of Healthcare of Russia. 2023. ID: 264. URL: https://cr.minzdrav.gov.ru/schema/264_2 (date of access – 27.05.2024) (In Russ.)).


10. Государственный реестр лекарственных средств Минздрава России. Аллергостин. РУ: ЛП-№(001179)-(РГ-RU) от 05.09.2022. Общая характеристика лекарственного препарата. Листок-вкладыш – информация для пациента. Доступ: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=8b1d5e51-f714-4756-9613-e35567a378d1 (дата обращения – 27.05.2024) (State register of medicines of the Ministry of Healthcare of Russia. Allergostin. Registration certificate: ЛП-№(001179)-(РГ-RU) dated from 09/05/2022. General characteristics of the drug. Package leaflet – patient information. Доступ: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=8b1d5e51-f714-4756-9613-e35567a378d1 (date of access – 27.05.2024) (In Russ.)).


11. Van Steekelenburg J., Clement P.A., Beel M.H. Comparison of five new antihistamines (H1-receptor antagonists) in patients with allergic rhinitis using nasal provocation studies and skin tests. Allergy. 2002; 57(4): 346–50.


https://doi.org/10.1034/j.1398-9995.2002.1s3426.x. PMID: 11906367.


About the Autors

Laura Z. Bolieva, MD, Dr. Sci. (Medicine), professor, head of the Department of pharmacology with clinical pharmacology, North Ossetian State Medical Academy of the Ministry of Healthcare of Russia. Address: 362019, Vladikavkaz, 40 Pushkinskaya St.
E-mail: bolievalz@mail.ru
ORCID: https://orcid.org/0000-0002-3763-8994
Miroslava B. Tseboeva, MD, PhD (Medicine), associate professor, dermatovenereologist at Diamed LLC. Address: 362000, Vladikavkaz, 51 Tamaeva St.
E-mail: miradzuceva@rambler.ru


Similar Articles

Back to Content

Бионика Медиа